PEPTIDREAM INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,100 JPY | +0.62% |
|
+5.61% | +41.27% |
| Sales 2024 * | 43.25B 276M | Sales 2025 * | 37.88B 241M | Capitalization | 272B 1.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.26B 84.52M | Net income 2025 * | 8.35B 53.19M | EV / Sales 2024 * | 6.15 x |
| Net cash position 2024 * | 6.39B 40.71M | Net cash position 2025 * | 21B 134M | EV / Sales 2025 * | 6.63 x |
| P/E ratio 2024 * |
20.4
x | P/E ratio 2025 * |
32.4
x | Employees | 603 |
| Yield 2024 * |
-
| Yield 2025 * |
0.1% | Free-Float | 73.93% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.62% | ||
| 1 week | +5.61% | ||
| Current month | +6.65% | ||
| 1 month | +7.03% | ||
| 3 months | +49.31% | ||
| 6 months | +77.29% | ||
| Current year | +41.27% |
1 week
1 956.50
2 139.00
1 month
1 797.002 139.00
Current year
1 224.502 139.00
1 year
1 039.002 424.50
3 years
1 039.005 560.00
5 years
1 039.006 540.00
10 years
861.256 540.00
| Managers | Title | Age | Since |
|---|---|---|---|
Patrick Reid
CEO | Chief Executive Officer | 49 | 06-12-31 |
| Director of Finance/CFO | 46 | 17-12-31 | |
Keiichi Masuya
COO | Chief Operating Officer | 55 | 14-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Reid
CEO | Chief Executive Officer | 49 | 06-12-31 |
Michio Sasaoka
BRD | Director/Board Member | 74 | 12-04-30 |
Junko Morita
BRD | Director/Board Member | 53 | 21-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.03% | 15 M€ | -4.01% | ||
| 0.54% | 14 M€ | +13.21% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 2,100 | +0.62% | 447 100 |
| 24-06-07 | 2,087 | +0.89% | 462,400 |
| 24-06-06 | 2,068 | -0.67% | 858,400 |
| 24-06-05 | 2,082 | +2.79% | 965,800 |
| 24-06-04 | 2,026 | +1.89% | 640,600 |
Delayed Quote Japan Exchange, June 10, 2024 at 02:00 am EDT
More quotes
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2,087
JPY
Average target price
2,850
JPY
Spread / Average Target
+36.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.27% | 1.73B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +0.76% | 22.78B | |
| -10.58% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- 4587 Stock
